Denali Therapeutics (DNLI) Competitors $14.70 -0.21 (-1.38%) Closing price 07/3/2025 03:08 PM EasternExtended Trading$14.69 -0.01 (-0.03%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, LNTH, and NUVLShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Lantheus (LNTH), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Lantheus Nuvalent Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Which has higher valuation & earnings, DNLI or BEAM? Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M6.46-$422.77M-$2.67-5.50Beam Therapeutics$63.52M31.69-$376.74M-$4.61-4.34 Do analysts rate DNLI or BEAM? Denali Therapeutics presently has a consensus price target of $33.71, indicating a potential upside of 129.43%. Beam Therapeutics has a consensus price target of $48.75, indicating a potential upside of 143.51%. Given Beam Therapeutics' higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is DNLI or BEAM more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -609.24%. Denali Therapeutics' return on equity of -35.90% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -35.90% -32.41% Beam Therapeutics -609.24%-44.24%-30.97% Does the media prefer DNLI or BEAM? In the previous week, Beam Therapeutics had 6 more articles in the media than Denali Therapeutics. MarketBeat recorded 8 mentions for Beam Therapeutics and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.22 beat Beam Therapeutics' score of 0.72 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, DNLI or BEAM? Denali Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Do institutionals & insiders have more ownership in DNLI or BEAM? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryDenali Therapeutics and Beam Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.13B$2.88B$5.49B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-5.5021.5627.4720.28Price / Sales6.46244.81408.86121.46Price / CashN/A41.9536.6357.47Price / Book1.727.518.095.68Net Income-$422.77M-$55.05M$3.17B$248.96M7 Day Performance4.22%4.61%2.81%3.30%1 Month Performance1.91%4.89%3.67%5.20%1 Year Performance-31.01%5.84%35.41%21.37% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.535 of 5 stars$14.70-1.4%$33.71+129.4%-31.0%$2.13B$330.53M-5.50430BEAMBeam Therapeutics2.7495 of 5 stars$17.01+1.3%$48.75+186.6%-14.7%$1.71B$63.52M-3.69510VRNAVerona Pharma PLC American Depositary Share2.6682 of 5 stars$94.58+0.8%$101.10+6.9%+480.4%$8.05B$42.28M-47.2930Positive NewsAnalyst ForecastROIVRoivant Sciences1.9619 of 5 stars$11.27-1.1%$17.50+55.3%+3.5%$7.66B$29.05M-45.08860ELANElanco Animal Health2.2634 of 5 stars$14.29flat$15.17+6.1%+3.6%$7.10B$4.44B19.319,000Analyst ForecastRVMDRevolution Medicines4.5767 of 5 stars$36.79-0.3%$67.58+83.7%+0.2%$6.85B$11.58M-9.20250Analyst RevisionLEGNLegend Biotech3.2781 of 5 stars$35.49+2.5%$76.20+114.7%-23.0%$6.52B$627.24M-60.152,609Analyst ForecastGRFSGrifols4.0574 of 5 stars$9.04+2.0%$10.30+13.9%+36.7%$6.22B$7.81B7.7323,822TGTXTG Therapeutics3.1747 of 5 stars$35.99-2.0%$40.80+13.4%+98.0%$5.71B$386.39M149.96290LNTHLantheus4.4619 of 5 stars$81.86+0.5%$130.50+59.4%-0.4%$5.66B$1.53B23.26700NUVLNuvalent3.7597 of 5 stars$76.30-4.2%$119.60+56.7%+11.5%$5.48BN/A-17.3840Insider Trade Related Companies and Tools Related Companies Beam Therapeutics Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Revolution Medicines Competitors Legend Biotech Competitors Grifols Competitors TG Therapeutics Competitors Lantheus Competitors Nuvalent Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNLI Stock Alerts